Viking Therapeutics

YTD

ALL

Trade Viking Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VKTX

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A.

CEO

Brian Lian

CEOBrian Lian

Employees

Employees53

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

2012

Founded2012

Employees

Employees53

VKTX Key Statistics

Market cap

3.95B

Market cap3.95B

Price-Earnings ratio

-7.19

Price-Earnings ratio-7.19

Dividend yield

—

Dividend yield—

Average volume

2.28M

Average volume2.28M

High today

$34.08

High today$34.08

Low today

$32.96

Low today$32.96

Open price

$33.16

Open price$33.16

Volume

1.96M

Volume1.96M

52 Week high

$43.15

52 Week high$43.15

52 Week low

$22.96

52 Week low$22.96

Stock Snapshot

As of today, Viking Therapeutics(VKTX) shares are valued at $33.30. The company's market cap stands at 3.95B, with a P/E ratio of -7.19.

On 2026-08-06, Viking Therapeutics(VKTX) stock moved within a range of $32.96 to $34.08. With shares now at $33.30, the stock is trading +1.0% above its intraday low and -2.3% below the session's peak.

Trading volume for Viking Therapeutics(VKTX) stock has reached 1.96M, versus its average volume of 2.28M.

Over the past 52 weeks, Viking Therapeutics(VKTX) stock has traded between a high of $43.15 and a low of $22.96.

VKTX News

Simply Wall St 2d

Does Viking’s Expanded Shelf and ATM Funding Shift the Bull Case For Viking Therapeutics?

In late July 2026, Viking Therapeutics reported a wider Q2 net loss of US$128.02 million and filed both a universal shelf registration and a US$500 million at-t...

TipRanks 6d

Viking Therapeutics: Why This Clinical-Stage, Licensed-Technology Play Is a Highly Speculative Bet for Equity Investors

Viking Therapeutics (VKTX) has disclosed a new risk, in the Accounting & Financial Operations category. Unlock powerful investing tools with TipRanks Premium t...

The Motley Fool 6d

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target - The Motley Fool

...

Analyst ratings

89%

of 19 ratings

Buy

89.5%

Hold

10.5%

Sell

More VKTX News

Simply Wall St 6d

This Insider Has Just Sold Shares In Viking Therapeutics

Some Viking Therapeutics, Inc. ( ) shareholders may be a little concerned to see that the President, Brian Lian, recently sold a substantial US$4.9m worth of st...

Benzinga 7d

Viking Therapeutics Stock Moves Lower: What's Going On?

Viking Therapeutics stock is showing weakness. What’s pulling VKTX shares down? Viking Beats Earnings Estimates but Stock Faces Selling Pressure The quarter end...

People also own

Based on the portfolios of people who own VKTX. This list is generated using Robinhood data, and it’s not a recommendation.

Novo Nordisk

Plug Power

Corbus Pharmaceuticals

Tilray Brands

Pfizer

Moderna

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.